Does the timing of cabergoline administration impact rates of ovarian hyperstimulation syndrome?
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
ObjectiveDoes the timing of cabergoline administration impact the rate of mild/moderate ovarian hyperstimulation syndromein women with a GnRH agonist trigger?MethodsWe conducted a retrospective cohort analysis of 285 in-vitro fertilization patients at risk of OHSS who received a GnRHagonist trigger from 2011 to 2019 at McGill University Health Centre. Group 1 (Trig, n=101) began taking cabergoline0.5 mg orally for 7 days at the time of GnRH agonist trigger, while Group 2 (Retriev, n=184) started taking cabergolineon the day of oocyte retrieval. The rates of OHSS were then compared between the groups using analysis of varianceand chi-square analysis, where appropriate. ResultsThe baseline demographic characteristics of the two groups were similar. Trig appeared to be at a slightly higherrisk of OHSS based on a significantly higher antral follicle count (20.2±4.2 vs. 19.0±4.3; P=0.02), higher number ofstimulated follicles >10 mm at trigger (25.7±7.0 vs. 22.8±8.3, P=0.003), and higher peak serum E2 level (17,325±2,542vs. 14,822±3,098; P=0.0001). The Trig group had lower rates of mild and moderate OHSS (24% vs. 36%; P=0.045). Neither group had any patients who developed severe OHSS. Trig had fewer patients presenting with pelvic free fluid(13% vs. 23%; P=0.03), lower hematocrit (37.8±4.8% vs. 40.5±4.2%; P=0.0001), higher albumin concentrations (30.4±2.7vs. 29.5±2.0; P=0.01), and lower potassium concentrations (3.9±0.5 vs. 4.2±0.7; P=0.0002). ConclusionCabergoline at the time of trigger as compared to the time of collection should be investigated to assess its role inreducing the rates of mild/moderate OHSS.
Abstract
ObjectiveDoes the timing of cabergoline administration impact the rate of mild/moderate ovarian hyperstimulation syndromein women with a GnRH agonist trigger?MethodsWe conducted a retrospective cohort analysis of 285 in-vitro fertilization patients at risk of OHSS who received a GnRHagonist trigger from 2011 to 2019 at McGill University Health Centre. Group 1 (Trig, n=101) began taking cabergoline0.5 mg orally for 7 days at the time of GnRH agonist trigger, while Group 2 (Retriev, n=184) started taking cabergolineon the day of oocyte retrieval. The rates of OHSS were then compared between the groups using analysis of varianceand chi-square analysis, where appropriate. ResultsThe baseline demographic characteristics of the two groups were similar. Trig appeared to be at a slightly higherrisk of OHSS based on a significantly higher antral follicle count (20.2±4.2 vs. 19.0±4.3; P=0.02), higher number ofstimulated follicles >10 mm at trigger (25.7±7.0 vs. 22.8±8.3, P=0.003), and higher peak serum E2 level (17,325±2,542vs. 14,822±3,098; P=0.0001). The Trig group had lower rates of mild and moderate OHSS (24% vs. 36%; P=0.045). Neither group had any patients who developed severe OHSS. Trig had fewer patients presenting with pelvic free fluid(13% vs. 23%; P=0.03), lower hematocrit (37.8±4.8% vs. 40.5±4.2%; P=0.0001), higher albumin concentrations (30.4±2.7vs. 29.5±2.0; P=0.01), and lower potassium concentrations (3.9±0.5 vs. 4.2±0.7; P=0.0002). ConclusionCabergoline at the time of trigger as compared to the time of collection should be investigated to assess its role inreducing the rates of mild/moderate OHSS.
참고문헌 (24)
- Garcia-Velasco JA, "How to avoid ovarian hyperstimulation syndrome : a new indication for dopamine agonists", Reprod Biomed Online, 18(Suppl 2), pp.71~75 (2009)
- Corbett S, "Special Contributor. The prevention of ovarian hyperstimulation syndrome", J Obstet Gynaecol Can, 36, pp.1024~1033 (2014)
- Schirmer DA 3rd, "Ovarian hyperstimulation syndrome after assisted reproductive technologies: trends, predictors, and pregnancy outcomes", Fertil Steril, 114, pp.567~578 (2020)
- Fatemi HM, "Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and “freeze-all” approach in GnRH antagonist protocol", Fertil Steril, 101, pp.1008~1011 (2014)
- Gurbuz AS, "Gonadotrophinreleasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome : a report of three cases", Reprod Biomed Online, 29, pp.541~544 (2014)
- Mahajan N, "Early onset ovarian hyperstimulation syndrome despite use of segmentation approach and ovarian hyperstimulation syndrome prophylaxis", J Hum Reprod Sci, 8, pp.234~238 (2015)
- Tang H, "Cabergoline for preventing ovarian hyperstimulation syndrome", Cochrane Database Syst Rev, (2), pp.CD008605~ (2012)
- Shaltout A, "Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study", Eur J Obstet Gynecol Reprod Biol, 165, pp.254~258 (2012)
- Gille H, "Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants", J Biol Chem, 276, pp.3222~3230 (2001)
- Kılıç N, "Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization", intracytoplasmic sperm injection treatment cycles : a randomized controlled study, 2015, pp.5, 123~127
- Ferraretti AP, "Dopamine treatment for severe ovarian hyperstimulation syndrome", Hum Reprod, 7, pp.180~183 (1992)
- Baumgarten M, "Do dopamine agonists prevent or reduce the severity of ovarian hyperstimulation syndrome in women undergoing assisted reproduction a systematic review and metaanalysis", Hum Fertil, 16, pp.168~174 (2013)
- Leitao VM, "Cabergoline for the prevention of ovarian hyperstimulation syndrome : systematic review and meta-analysis of randomized controlled trials", Fertil Steril, 101, pp.664~675 (2014)
- Tang H, "Dopamine agonists for preventing ovarian hyperstimulation syndrome", Cochrane Database Syst Rev, 11, pp.CD008605~ (2016)
- Seow KM, "Clinical outcome according to timing of cabergoline initiation for prevention of OHSS : a randomized controlled trial", Reprod Biomed Online, 26, pp.562~568 (2013)
- Zimmermann RC, "Vascular endothelial growth factor receptor 2-mediated angiogenesis is essential for gonadotropin-dependent follicle development", J Clin Invest, 112, pp.659~669 (2003)
- Gaafar S, "Early onset of cabergoline therapy for prophylaxis from ovarian hyperstimulation syndrome(OHSS) : a potentially safer and more effective protocol", Reprod Biol, 19, pp.145~148 (2019)
- Alvarez C, "Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment : a pilot study", Hum Reprod, 22, pp.3210~3214 (2007)
- Timmons D, "Ovarian hyperstimulation syndrome : a review for emergency clinicians", Am J Emerg Med, 37, pp.1577~1584 (2019)
- Rotterdam ESHRE, "ASRM-Sponsored PCOS Consensus Workshop Group", Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome, 2004, pp.81, 19~25
- Seyhan A, "Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG", Hum Reprod, 28, pp.2522~2528 (2013)
- Ata B, "Reply : GnRHa trigger and modified luteal support with one bolus of hCG should be used with caution in extreme responder patients", Hum Reprod, 28, pp.2594~2595 (2013)
- Rose BI, "Approaches to oocyte retrieval for advanced reproductive technology cycles planning to utilize in vitro maturation : a review of the many choices to be made", J Assist Reprod Genet, 31, pp.1409~1419 (2014)
- Navot D, "Ovarian hyperstimulation syndrome in novel reproductive technologies : prevention and treatment", Fertil Steril, 58, pp.249~261 (1992)